Theresa M. LaVallee

Theresa LaVallee, Vice President of Translational Medicine, joined Kolltan in 2013.

Dr. LaVallee has more than 25 years of research and industry experience with broad knowledge and proven success in the discovery and development of drug candidates in oncology and inflammation.

She most recently served as Senior Director, Translational Medicine at MedImmune, the global biologics arm of AstraZeneca. At MedImmune, Dr. LaVallee designed and implemented translational and biomarker strategies for oncology drug development and was a key contributor to IND filings and clinical development for many product candidates in oncology diseases.

Previously, she held multiple research positions at EntreMed, including Senior Director, Cell Biology.

Dr. LaVallee is author or co-author of more than 40 publications and abstracts, with a focus on receptor tyrosine kinases and their key roles in disease pathways.

She received her Ph.D. degree from the University of California, Los Angeles and her B.A. degree from the University of California, Santa Barbara. Dr. LaVallee completed her postdoctoral research at the American Red Cross Holland Laboratory.

Theresa M. LaVallee is the Chief Development Officer at Coherus Biosciences, based in United States, North America. With a background in Biotechnology, Theresa M. LaVallee has a rich history of leadership and innovation.Theresa M. LaVallee studied Ph.D. unknown at University of California, Los Angeles. Explore their detailed professional journey, key connections, and contributions to the industry on our platform.